Shardendu Kumar Mishra

Dr. Shardendu Kumar Mishra


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
GTGarima Tripathi
Garima Tripathi
NKNavneet Kishore
Navneet Kishore
RSRakesh K. Singh
Rakesh K. Singh
ASArchana Singh
Archana Singh
VTVINOD TIWARI
VINOD TIWARI

30 April 2024 in Oriental Journal of Chemistry
Verified
Journal Article
Open access
PDF file
GGGauri Goyal
Gauri Goyal
VKVinay Kumar
Vinay Kumar
HTHimani Tyagi
Himani Tyagi
PVPriyanshi Varshney
Priyanshi Varshney
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
SCSanjeev Chauhan
Sanjeev Chauhan
The phenomenon of wound healing encompasses a coordinated sequence of cellular and biochemical phases collaborating synergistically to promote the restoration of the injured tissue. Tissue repair is complex, posing challenges in wound management. Healing involves three phases: inflammatory, proliferative, and remodeling. Treatments include antibiotics, antiseptics, and extracts, but synthetic drugs have limitations. There is growing interest in plant-based formulations for effective wound treatment. Medicinal plants are increasingly recognized for their wound healing potential with lower side effects, particularly in diabetic, infected, or open wounds, supported by studies highlighting various identified mechanisms for improved healing. Medicinal plants such as Allium sativum, Boerhavia diffusa, Calendula officinalis, Crocus sativus, Curcuma longa L., Glycyrrhiza glabra L., Melaleuca alternifolia, Woodfordia fruticosa, etc. have demonstrated wound healing properties and have proven effective in treating wounds. This review highlights medicinal plants in wound healing, emphasizing in-vivo models, specifically examining their effectiveness in excision and incision wound healing.

30 December 2024 in Biomedical and Pharmacology Journal
Verified
Journal Article
Open access
RGRoma Ghai
Roma Ghai
AMAshu Mittal
Ashu Mittal
DPDeepali Pandey
Deepali Pandey
SAShamshir Alam
Shamshir Alam
SKShikha Kaushik
Shikha Kaushik
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
Drug administration at similar doses in patients can often lead to various clinical responses. It has been hypothesized that genetics primarily accounts for variation in drug efficacy and toxicity in individuals. Personalized medicine has been a breakthrough achieved by the Human Genome Project which contributes to enhancing quality-based patient care. It deals with the customization of medication considering the distinct genetic and proteomic data that underpins the originality of every patient and every instance of therapeutic intervention. Many cases have shown that inter-individual differences related to drug response can be traced to genetic polymorphism in the gene alleles that codes for metabolizing enzymes, drug transporters, and genetic variations in a person’s Major Histocompatibility Complex (MHC). So, the paper throws an insight into epidemiological variations due to genetics, variations in response based on metabolic parameters, and transporters. It also covers genetic variation related to immune-related drug toxicities. Pharmacogenetic testing plays an important role in achieving more precise personalized therapeutics for better public health. The paper discusses various tests for human leukocyte antigen variants and metabolic variants. Every technology inclusion comes with advantages and limitations so personalized medicine also faces certain challenges which are discussed in the paper. Once personalized medicine is used in clinical settings, patients will be able to receive the best medications for them based on their unique genetic and protein profiles.

1 January 2024 in Asian Journal of Pharmaceutical Research and Health Care
Verified
Journal Article
Open access
SCShubham Chaudhary
Shubham Chaudhary
GKGarima Kapoor
Garima Kapoor
VCVijul Kumar Choudhary
Vijul Kumar Choudhary
RBRubina Bhutani
Rubina Bhutani
KNK. Nagarajan
K. Nagarajan
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
Context: Hypertension, a prevalent cardiovascular condition characterized by elevated systemic arterial pressure, presents a significant global health challenge. Despite various therapeutic interventions, comprehending the intricate molecular mechanisms behind hypertension and devising effective treatments remains an ongoing objective. Aim: This study employs network pharmacology and molecular docking to investigate the potential repurposing of budipine, a dopamine facilitator used in parkinsonism treatment, for addressing hypertension. Materials and Methods: The in-silico tools like network analysis, molecular docking, pivotal nodes, pathways, and binding affinity, molecular interaction linked to hypertensive disease proteins, unveiling potential therapeutic targets and modes of action. In this study, five potential targets (OPRK1, ‘OPRD1, ‘OPRM1, ‘HSD11B2, and PIK3R1) and PDB (6b73) were involved in the management of hypertensive disease. Results: Molecular docking was utilized to affirm the efficacy of budipine; binding affinity and interactions between budipine and the OPRK1 target (PDB ID: 6b73) were noteworthy, registering a robust binding energy of −7.8 Kcal/mol. In comparison, the standard ligands, enalapril and diltiazem, exhibited binding energies of −7.7 Kcal/mol and −6.3 Kcal/mol, respectively. These findings underscore the potent binding capabilities of budipine with the OPRK1 target, suggesting its potential efficacy in addressing hypertensive diseases through modulation of the OPRK1 pathway. Conclusion: To sum up, this study highlights the usefulness of network pharmacology and molecular docking for investigating how drugs, like budipine, work to treat high blood pressure. The comprehensive method used in this study provides a better grasp of hypertension and lays the groundwork for developing a precise and efficient treatment.

10 October 2025 in Phytomedicine Plus
Verified
Journal Article
Open access
SMShardendu Kumar Mishra
Shardendu Kumar Mishra
DPDeepali Pandey
Deepali Pandey
ONOmkar S. Nille
Omkar S. Nille
SRShital J. Rajmane
Shital J. Rajmane
GNGuruprasad C. Nille
Guruprasad C. Nille

30 August 2025 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
GNGuruprasad C. Nille
Guruprasad C. Nille
MBMonisha Bhuyan
Monisha Bhuyan
LGLaxmi Narayan Gupta
Laxmi Narayan Gupta
MAMohd Ali
Mohd Ali
CTChandra Shekhar Pati Tripathi
Chandra Shekhar Pati Tripathi
ACAnand Kumar Chaudhary
Anand Kumar Chaudhary
Yashad Bhasma (YB), the incinerated metal ash of zinc, has been used for centuries in Ayurveda to address a variety of conditions, including eye diseases, diabetes mellitus, anemia, respiratory illnesses, etc. OBJECTIVE: This research aimed to synthesize and characterize YB and to evaluate its potential antimicrobial, antioxidant, and anti-angiogenic activities. In this study, YB is synthesized by optimizing the traditional method. Morphological and physicochemical characterization are performed using XRD, XPS, SEM, TEM, EDAX, DLS, TGA-DSC, and FTIR. The antimicrobial activity of YB is assessed using the well diffusion technique against the gram-positive bacterium Staphylococcus aureus (S. aureus) and the gram-negative bacterium Escherichia coli (E. coli). The antioxidant potential is evaluated using the 1,1-Diphenyl-2-Picrylhydrazyl (DPPH) radical scavenging assay and Nitric oxide (NO) radical scavenging assay. A chick chorioallantoic membrane (CAM) assay is performed on fertilized chick eggs to study the anti-angiogenesis potential of YB. The XRD patterns of YB showed the presence of cubic and hexagonal phases of ZnS having average crystallite size of 32.66 nm. XPS data supports the formation of ZnS phase of YB. SEM and TEM data confirmed the size of YB NPs in a range of 250-350 nm. The EDAX analysis confirmed the presence of Zn (37.2 %) and S (21.18 %). The mean particle diameter was 361 nm in DLS. TGA-DSC findings verified that the synthesized material is stable up to 435.80 °C. The FTIR confirms the presence of organic moieties in YB along with ZnS phase. YB effectively inhibited the growth of S. aureus and E. coli. The ability of YB to scavenge DPPH and NO radicals is found to be concentration dependent (50-250 μg/mL). The study also demonstrated that YB has notable antioxidant activity. The disappearance of blood vessels beneath the sample-loaded disk after 7 days indicated the effective anti-angiogenic properties of YB. Altogether, YB exhibited significant antimicrobial, noteworthy antioxidant, and anti-angiogenic activities, indicating its potential as a promising therapeutic agent.